{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"ORR is defined as percentage of participants with complete response (CR), VGPR and partial response (PR). CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and \\<5% plasma cells in bone marrow; normal free light chain (FLC) ratio of 0.26-1.65; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum M-protein + urine M-protein level \\<100 mg/24 hours; and PR: \\>=50% reduction of serum M protein and reduction in 24-hour urinary M protein by \\>=90%/to \\<200 mg/24 hours; In addition, if present at baseline, \\>=50% reduction in size of soft tissue plasmacytomas; no known evidence of progressive/new bone lesions. The percentage of participants were rounded off to the single decimal point.","groups":[{"description":"Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or up to 5 years.","id":"OG000","title":"Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg"}],"paramType":"NUMBER","populationDescription":"Response-evaluable population included participants who received at least 1 dose of ixazomib, had measurable disease during the screening period, and had at least 1 postbaseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}